47 results
Page 2 of 3
8-K
EX-99.1
1ffb2opdcr
4 Jun 21
POINT Biopharma Announces First Patients
4:22pm
425
EX-99.1
gbhjzkci
4 Jun 21
Business combination disclosure
4:20pm
8-K
EX-99.1
3km504n3h2iiddr
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
425
EX-99.1
acr dtz4bzbeee
1 Jun 21
Business combination disclosure
4:30pm
S-4/A
8v4f yyxr7i25ef
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
8-K
EX-99.1
8btsh6gil8in00b b8
28 Apr 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
5:13pm
425
EX-99.1
bfzgy
28 Apr 21
Business combination disclosure
5:11pm
S-4
n1zsti32s9a
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
dnxrzic
18 Mar 21
Financial Statements and Exhibits
9:08am
8-K
EX-99.1
tt0itmi0o go1va94
15 Mar 21
Public Investor Presentation Transcript
5:20pm
425
EX-99.1
vhw7dca
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
oaz5etws
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am
10-K
s5hil
5 Mar 21
Annual report
8:13am
10-Q
1uv18otcosv6el3 59
20 Aug 20
Quarterly report
4:15pm
8-K
EX-99.1
vogcn8m
16 Jul 20
Report of Independent Registered Public Accounting Firm
4:30pm
8-K
EX-99.1
1jljdi1z7gt37m85m4
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm